Breast cancer is the most common malignancy in women worldwide, with a relatively high proportion of patients experiencing resistance to standard treatments. Cellular immunotherapy (CI), which is based on the extraction, modification, and re-infusion of the patient's immune cells, is showing promising results in these patients. Among CI possible approaches, adoptive cell therapy (ACT) and dendritic cell (DC) vaccination are the most comprehensively explored in both primary/translational research studies and clinical trials. ACT may include the use of tumor-infiltrating lymphocytes (TILs), T cell receptor (TCR)-, or chimeric antigen receptor (CAR)-engineered T-cells. There are indications suggesting that a biomarker-based approach might be beneficial in effectively selecting breast cancer patients for CI. Here, we sought to provide the current knowledge of CI in breast cancer, focusing on candidate biomarkers, ongoing clinical trials, limitations, and immediate future perspectives.
Cellular immunotherapy in breast cancer: The quest for consistent biomarkers / K. Venetis, M. Invernizzi, E. Sajjadi, G. Curigliano, N. Fusco. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 90(2020 Nov).
|Titolo:||Cellular immunotherapy in breast cancer: The quest for consistent biomarkers|
VENETIS, KONSTANTINOS (Primo)
CURIGLIANO, GIUSEPPE (Penultimo) (Corresponding)
FUSCO, NICOLA (Ultimo) (Corresponding)
|Parole Chiave:||Biomarkers; Breast cancer; Cancer vaccine; CAR-T; Cellular immunotherapy; T-cells|
|Settore Scientifico Disciplinare:||Settore MED/08 - Anatomia Patologica|
Settore MED/06 - Oncologia Medica
|Data di pubblicazione:||nov-2020|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.ctrv.2020.102089|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
| [Cancer Treat Rev] cellular immunotherapy main.pdf||Publisher's version/PDF||Administrator Richiedi una copia|